Two-Drug cocktail shows promise against tough liver cancer
NCT ID NCT03211416
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a combination of two drugs—sorafenib (a targeted therapy) and pembrolizumab (an immunotherapy)—in 37 people with advanced liver cancer that had spread. The goal was to see if the combo could shrink tumors and help people live longer. The trial was early-stage, so results are promising but not yet proven for widespread use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sorafenib and pembrolizumab (a targeted therapy and an immunotherapy drug combination)
- What this could lead to
- If it works, this combination could offer a new treatment option for advanced liver cancer, potentially shrinking tumors and extending survival.
- What could go wrong
- This was a small, early-phase trial (37 people), so results may not apply to everyone. Side effects from the drug combination can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ADULT HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Robert H Lurie Comprehensive Cancer Center
Chicago, Illinois, 60611, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.